Arrowhead Pharmaceuticals(ARWR) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a net income of $30.8 million for Q1 2026, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, which received FDA approval as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [4][5] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. and a significant proportion of patients enrolling in the patient support program [6][19] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early data reported [9][10] Market Data and Key Metrics Changes - The company anticipates launching Redemplo in Canada and select EU countries later in 2026, with Sanofi marketing it in Greater China [8] - The U.S. market for mixed hyperlipidemia is estimated to include approximately 20 million people, representing a significant opportunity for the ARO-DimerPA candidate [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value of medicines to patients and healthcare systems [6] - Arrowhead aims to become cash flow positive and self-sustaining from commercial sales, with a strong emphasis on expanding its cardiometabolic and CNS portfolios [15][12] - The company has strengthened its balance sheet with $1.33 billion in gross proceeds from various transactions, enabling further development and commercialization efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to build on recent achievements and highlighted the potential for significant revenue opportunities from upcoming product launches [4][17] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran, which could represent a $3-$4 billion opportunity [38] Other Important Information - The company has received breakthrough therapy designation for plozasiran, expediting its development for severe hypertriglyceridemia [25] - Arrowhead's proprietary TRiM platform is being utilized to enhance drug delivery across various tissues, including the CNS [12] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [42][43] Question: What are the expectations for the obesity programs and FDA discussions? - Discussions with the FDA are expected around mid-year, and the company does not need all data from cohorts before determining the next steps [46] Question: What level of LDL-C and triglyceride reduction is expected for ARO-DimerPA? - A reduction of around 40%-50% in LDL and triglycerides would be encouraging for advancing the asset [48][49] Question: How is pricing being considered for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [51] Question: What are the expectations for pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [54] Question: How is payer feedback for Redemplo shaping discussions for SHTG? - Payer discussions are focused on ensuring coverage for high-risk patients, with a strong emphasis on the clinical and economic value of Redemplo [57][60]